<DOC>
	<DOCNO>NCT01171924</DOCNO>
	<brief_summary>This phase Ib open label , expansion study CUDC-101 patient advanced head neck , gastric , breast , liver , non-small cell lung cancer tumor . CUDC-101 multi-targeted agent design inhibit epidermal growth factor receptor ( EGFR ) , human epidermal growth factor receptor Type 2 ( Her2 ) histone deacetylase ( HDAC ) . The study design compare safety tolerability CUDC-101 administer maximum tolerate dose either 5 days/week schedule 3 days/week schedule .</brief_summary>
	<brief_title>A Phase Ib Expansion Study Investigating Safety , Efficacy , Pharmacokinetics Intravenous CUDC-101 Subjects With Advanced Head Neck , Gastric , Breast , Liver Non-small Cell Lung Cancer Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Subjects histopathologically confirm diagnosis advance breast , gastric , head neck , liver nonsmall cell lung cancer . For subject nonsmall cell lung cancer : Most recent treatment must erlotinib subject must radiographic partial complete response treatment define RECIST criterion currently progress document response . A documented mutation EGFR exons 19 21 Subjects must standard care option refuse standard therapy Measurable evaluable disease Age ≥ 18 year ECOG performance &lt; 2 Life expectancy ≥ 3 month If female , neither pregnant lactating If child bear potential , must use adequate birth control Absolute neutrophil count ≥ 1,500/µL ; platelet ≥ 100,000/µL ; Creatinine ≤ 1.5x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60mL/min/1.73m2 Total bilirubin ≤ 1.5x ULN ; AST/ALT ≤ 2.5x ULN . In subject document liver metastasis , AST/ALT may ≤ 5x ULN Prothrombin time ≤1.5x ULN , unless receive therapeutic anticoagulation Serum magnesium potassium within normal limit ( may use supplement achieve normal value ) Subjects brain metastasis eligible control stable dose ≤ 10mg prednisone/day equivalent dose steroid Able render inform consent follow protocol requirement . Anticancer therapy within 4 week study entry . Use investigational agent ( ) within 30 day study entry History cardiac disease New York Heart Association ( NYHA ) Class II great congestive heart failure ( CHF ) , myocardial infarction ( MI ) unstable angina past 6 month prior Day 1 treatment , serious arrhythmia require medication treatment . Known infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. Subjects liver cancer hepatitis may eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>HDAC</keyword>
	<keyword>Her2</keyword>
	<keyword>CUDC-101</keyword>
</DOC>